1-cyclohexyl-N-methylmethanamine hydrochloride | 161353-93-1

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 1-cyclohexyl-N-methylmethanamine hydrochloride
• 英文别名: (Cyclohexylmethyl)methylamine hydrochloride；1-cyclohexyl-N-methylmethanamine;hydrochloride
• CAS: 161353-93-1
• 化学式: C₈H₁₇N*ClH
• mdl: MFCD08707972
• 分子量: 163.691
• InChiKey: AZYHUEHPKHAEKO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.92
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  12
• 氢给体数：
  2
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  1-cyclohexyl-N-methylmethanamine hydrochloride 在 吡啶 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 反应 41.25h， 生成 N-(cyclohexylmethyl)-10-((5-(dimethylcarbamoyl)-2-oxo-4-phenylpyridin-1(2H)-yl)methyl)-10-hydroxy-N-methyl-7-azaspiro[4.5]decane-7-carboxamide
  参考文献：
  名称：

  WO2020115501A5

  摘要：

  公开号：

  WO2020115501A5
• 作为产物：
  描述：

  N-环己基甲基氨基甲酸叔丁酯 在 盐酸 、 sodium hydride 作用下， 以 四氢呋喃 、 乙酸乙酯 、 mineral oil 为溶剂， 反应 1.5h， 生成 1-cyclohexyl-N-methylmethanamine hydrochloride
  参考文献：
  名称：

  INDOLINE DERIVATIVES

  摘要：

  本发明提供了一种新的吲哚啉衍生物，或者其药理学上可接受的盐，或者所述衍生物的溶剂或其盐的溶剂，其由以下式（1）所代表，具有优异的丁酰胆碱酯酶抑制活性。在该式中，R1代表烷基，环烷基，杂环烷基，芳基，杂芳基，芳基烷基，杂芳基烷基，环烷基烷基，杂环烷基烷基，二氢呋喃基烷基，烯基，四氢萘基或吲哚基；R2代表氢原子，烷基，芳基烷基，环烷基烷基，杂芳基烷基，杂环烷基烷基，芳基或酰基；R3各自独立地代表氢原子，烷基或二烷基氨基甲酰基；R4各自独立地代表氢原子或烷基；R5代表氢原子或烷基。每个功能基团可能有取代基。

  公开号：

  US20110294850A1

文献信息

• [EN] 4-HYDROXYPIPERIDINE DERIVATIVES AND THEIR USE AS INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 19 (USP19)<br/>[FR] DÉRIVÉS DE 4-HYDROXYPIPÉRIDINE ET LEUR UTILISATION EN TANT QU'INHIBITEURS DE LA PROTÉASE 19 SPÉCIFIQUE DE L'UBIQUITINE
  申请人：ALMAC DISCOVERY LTD

  公开号：WO2019150119A1

  公开（公告）日：2019-08-08

  Inhibitors of ubiquitin specific protease 19 (USP19) of Formula (I) are provided, together with pharmaceutical compositions comprising said inhibitors, and methods of use thereof. The compounds can be used in in the treatment of muscular atrophy, obesity, insulin resistance or type II diabetes or in reducing the loss of muscle mass.

  提供了公式（I）的泛素特异性蛋白酶19（USP19）的抑制剂，以及包含该抑制剂的药物组合物，以及其使用方法。这些化合物可用于治疗肌肉萎缩、肥胖、胰岛素抵抗或2型糖尿病，或减少肌肉质量的流失。
• UREA COMPOUND OR SALT THEREOF
  申请人：Ishii Takahiro

  公开号：US20110172230A1

  公开（公告）日：2011-07-14

  [Object] To provide a compound which can be used for the treatment of a disease associated with fatty acid amide hydrolase (FAAH), particularly urinary frequency, urinary incontinence and/or overactive bladder. [Means for solution] It is confirmed that a urea compound chemical-structurally characterized by having a piperidine or piperazine ring or a salt thereof has an excellent FAAH-inhibitory activity, and thus the present invention is completed. The urea compound or its pharmaceutically acceptable salt of the present invention can increase the effective bladder capacity and ameliorate the state of urinary frequency, and is therefore useful as an agent for treating urinary frequency, urinary incontinence and/or overactive bladder.

  [目的] 提供一种化合物，可用于治疗与脂肪酸酰胺水解酶（FAAH）相关的疾病，特别是尿频、尿失禁和/或膀胱过度活动。 [解决方案] 确认具有哌啶或哌嗪环或其盐的尿素化合物在化学结构上具有出色的FAAH抑制活性，因此完成了本发明。本发明的尿素化合物或其药学上可接受的盐可以增加有效膀胱容量，改善尿频状态，因此可用作治疗尿频、尿失禁和/或膀胱过度活动的药物。
• Indoline derivatives
  申请人：Sugimoto Hachiro

  公开号：US08686024B2

  公开（公告）日：2014-04-01

  The present invention provides a novel indoline derivative or a pharmacologically acceptable salt thereof or a solvate of the derivative or a salt thereof represented by the following formula (1) that has an excellent butyrylcholinesterase inhibitory activity. In the formula, R1 represents an alkyl group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, a heteroaryl group, an arylalkyl group, a heteroarylalkyl group, a cycloalkylalkyl group, a heterocycloalkylalkyl group, a dihydrofurylalkyl group, an alkenyl group, a tetrahydronaphthyl group, or an indanyl group; R2 represents a hydrogen atom, an alkyl group, an arylalkyl group, a cycloalkylalkyl group, a heteroarylalkyl group, a heterocycloalkylalkyl group, an aryl group, or an acyl group; R3 each independently represents a hydrogen atom, an alkyl group, or a dialkylaminocarbonyl group; R4 each independently represents a hydrogen atom or an alkyl group; and R5 represents a hydrogen atom or an alkyl group. Each functional group may have a substituent.

  本发明提供了一种新型吲哚啉衍生物，或其药学上可接受的盐，或其衍生物或盐的溶剂，其表示为以下式（1），具有出色的丁酰胆碱酯酶抑制活性。在该式中，R1表示烷基，环烷基，杂环烷基，芳基，杂芳基，芳基烷基，杂芳基烷基，环烷基烷基，杂环烷基烷基，二氢呋喃基烷基，烯基，四氢萘基或吲哚基；R2表示氢原子，烷基，芳基烷基，环烷基烷基，杂芳基烷基，杂环烷基烷基，芳基或酰基；R3各自独立地表示氢原子，烷基或二烷基氨基甲酰基；R4各自独立地表示氢原子或烷基；R5表示氢原子或烷基。每个功能基团可以具有取代基。
• 4-HYDROXYPIPERIDINE DERIVATIVES AND THEIR USE AS INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 19 (USP19)
  申请人：Almac Discovery Limited

  公开号：EP3746432B1

  公开（公告）日：2022-12-14
• PHARMACEUTICAL COMPOUNDS AND THEIR USE AS INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 19 (USP19)
  申请人：ALMAC DISCOVERY LIMITED

  公开号：US20220033397A1

  公开（公告）日：2022-02-03

  Provided are USP19 inhibitors, methods of treating obesity, metabolic syndrome and/or diabetes using the USP19 inhibitor compounds, as well as those compounds for use in methods of treating obesity, metabolic syndrome and/or diabetes. Also provided are methods of treating muscular atrophy, for example cachexia or sarcopenia with USP19 inhibitor compounds, plus those a compounds for use in methods of treating muscular atrophy.